Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

June 30, 2023

Study Completion Date

August 13, 2025

Conditions
Metastatic Esophageal CarcinomaMetastatic Gastric CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaRecurrent Esophageal CarcinomaRecurrent Gastric CarcinomaRecurrent Gastroesophageal Junction AdenocarcinomaStage III Esophageal Cancer AJCC v7Stage III Gastric Cancer AJCC v7Stage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Unresectable Esophageal CarcinomaUnresectable Gastric CarcinomaUnresectable Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Olaparib

Give PO

BIOLOGICAL

Ramucirumab

Given IV

Trial Locations (32)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

32610

University of Florida Health Science Center - Gainesville, Gainesville

37204

Vanderbilt Breast Center at One Hundred Oaks, Nashville

37232

Vanderbilt University/Ingram Cancer Center, Nashville

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48334

Weisberg Cancer Treatment Center, Farmington Hills

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

77030

M D Anderson Cancer Center, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91786

City of Hope Upland, Upland

92882

City of Hope Corona, Corona

93534

City of Hope Antelope Valley, Lancaster

94115

UCSF Medical Center-Mount Zion, San Francisco

95817

University of California Davis Comprehensive Cancer Center, Sacramento

06418

Smilow Cancer Hospital-Derby Care Center, Derby

06824

Smilow Cancer Hospital Care Center-Fairfield, Fairfield

06437

Smilow Cancer Hospital Care Center - Guilford, Guilford

06105

Smilow Cancer Hospital Care Center at Saint Francis, Hartford

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

06473

Yale-New Haven Hospital North Haven Medical Center, North Haven

06477

Smilow Cancer Hospital-Orange Care Center, Orange

06790

Smilow Cancer Hospital-Torrington Care Center, Torrington

06611

Smilow Cancer Hospital Care Center-Trumbull, Trumbull

06708

Smilow Cancer Hospital-Waterbury Care Center, Waterbury

06385

Smilow Cancer Hospital Care Center - Waterford, Waterford

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

08903

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03008278 - Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter